Core Viewpoint - NurExone Biologic Inc. reported its financial results for Q2 2025, highlighting advancements in its exosome-based therapies for central nervous system injuries and outlining its strategic plans for future clinical trials and manufacturing processes [1][4]. Financial Results - The company raised C$2.3 million through a private placement on April 10, 2025, selling 3,543,238 units at C$0.65 each, with proceeds aimed at working capital and clinical development [6]. - Research and development expenses for Q2 2025 were US$0.70 million, an increase from US$0.51 million in Q2 2024, attributed to higher service provider costs and stock-based compensation [6]. - General and administrative expenses rose to US$1.13 million in Q2 2025 from US$0.81 million in Q2 2024, driven by increased salaries and service provider costs [6]. - The net loss for Q2 2025 was US$1.85 million, compared to a loss of US$1.33 million in the same quarter of 2024 [6]. Corporate Highlights and Business Update - The company plans to initiate a Phase 1/2a trial of its lead product ExoPTEN for acute spinal cord injury in 2026, pending regulatory approvals [6]. - NurExone reported new manufacturing process validation data supporting the scalability and consistency of exosome production, with plans for tech transfer to its U.S. subsidiary Exo-Top for GMP manufacturing [6]. - The company was accepted into the Advanced Regenerative Manufacturing Institute's HealthTech Hub Accelerator to bolster its U.S. growth and manufacturing strategy [6][12]. - NurExone expanded its preclinical data set and engaged in scientific forums to enhance visibility and strategic partnerships [12]. Management Commentary - The CEO emphasized the importance of de-risking scale and quality through a validation-led manufacturing process and advancing U.S. tech transfer planning [7]. - The CFO noted that the April 2025 Offering strengthened the company's cash position to support ExoPTEN and align spending with milestone objectives [8]. About the Company - NurExone Biologic Inc. is focused on developing regenerative exosome-based therapies for central nervous system injuries, with its lead product ExoPTEN targeting acute spinal cord and optic nerve injuries, which represent multi-billion-dollar markets [9]. - The company has established Exo-Top Inc. as a U.S. subsidiary to anchor its North American activities and growth strategy [9].

Core Viewpoint - NurExone Biologic Inc. has successfully closed a private placement and announced promising preclinical imaging results for its lead product ExoPTEN, which shows potential for spinal cord repair following injury [1][10][14]. Company Developments - The company closed a non-brokered private placement of 1,258,072 units at C$0.62 per unit, raising gross proceeds of C$780,004.64, intended for working capital [10][11]. - NurExone is preparing for its first-in-human clinical trial of ExoPTEN, pending regulatory approval [4][14]. Product and Research Insights - Preclinical imaging analysis indicates that ExoPTEN-treated animals exhibited more organized spinal cord tissue compared to untreated controls, with 100% of higher-dose group animals regaining motor function [2][3]. - MRI-Diffusion Tensor Imaging (MRI-DTI) results show that treated spinal cords had greater structural integrity, with higher Fractional Anisotropy (FA) values and lower Mean Diffusivity (MD) values near the injury site, suggesting healthier tissue architecture [5][6][8][9]. - The imaging results support the neuroprotective and regeneration-promoting activity of ExoPTEN in spinal cord injury [3][15]. Market Context - Spinal cord injuries present significant healthcare and economic challenges, with current treatments primarily focusing on stabilization rather than tissue repair. ExoPTEN aims to address this unmet need by supporting nerve repair and restoring function [4][14]. - The market for spinal cord injury treatments is substantial, with NurExone's lead product positioned in a multi-billion-dollar market [14].

Core Insights - NurExone Biologic Inc. announced that its exosomes outperformed a recognized commercial industry standard in key healing tasks such as nerve repair, wound repair, immune system modulation, and tissue rebuilding, indicating broad potential in therapeutic and aesthetic markets [1][6] Group 1: Exosome Performance - Independent study results showed NurExone's exosomes exhibit approximately 1.8-fold higher neurological potential, nearly double the anti-inflammatory activity, and a two-fold increase in tissue-regeneration and wound-healing signals compared to commercial benchmarks [4] - The exosomes produced by NurExone's U.S. subsidiary, ExoTOP Inc., are expected to deliver more than twice the wound-healing signals than the industry benchmark, suggesting applications in aesthetic skin rejuvenation, wound care, and orthopedic tissue repair [2][4] Group 2: Production and Technology - NurExone's exosomes are produced from a proprietary master cell bank, ensuring high-performance and reproducibility essential for clinical translation and future patient use [3] - The exosomes are enriched with microRNAs that support key healing tasks, as confirmed by a comprehensive analysis performed by TAmiRNA, an ISO13485-certified molecular-diagnostics laboratory [2][7] Group 3: Market Potential and Strategy - The company is focused on developing regenerative exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing strong preclinical data for treating acute spinal cord and optic nerve injuries, both of which are multi-billion-dollar markets [8] - ExoTOP is expected to generate multiple revenue streams and provide high-performance exosomes to partners across regenerative medicine as production scales in the U.S. [2][8]

Independent Study and Bioanalysis Suggests More Effective Nerve Repair and Faster Wound HealingTORONTO and HAIFA, Israel, Aug. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced that an independent study showed that exosomes produced by NurExone outperformed a recognized commercial industry standard in areas that strongly support key healing tasks including nerve repair, wound repair, calming the immune system and rebuildin ...

Core Points - NurExone Biologic Inc. has been named a finalist in Falling Walls Venture 2025, showcasing its potential in the field of science-based start-ups [1][2] - The company's lead product, ExoPTEN, aims to address central nervous system injuries, which impose significant personal and economic burdens [2][4] - NurExone will present its exosome-based regenerative therapy platform at the Falling Walls Science Summit in Berlin from November 6-9, 2025 [2][3] Company Overview - NurExone is a biotech company listed on TSX Venture Exchange, OTCQB, and Frankfurt, focusing on developing regenerative exosome-based therapies for central nervous system injuries [4] - ExoPTEN has shown promising preclinical data for treating acute spinal cord and optic nerve injuries, both of which represent multi-billion-dollar markets [4][10] - The company has received Orphan Drug Designation, facilitating its roadmap towards clinical trials in the U.S. and Europe [4] Event Participation - As a finalist, NurExone will have access to exclusive networking events, connecting with investors, strategic partners, and global thought leaders [3] - The Falling Walls Science Summit serves as a platform for finalists to pitch their innovations, with one being awarded the title 'Science Breakthrough of the Year' [3]

Core Points - NurExone Biologic Inc. has been named a finalist in the Falling Walls Venture 2025, showcasing its potential in the field of science-based start-ups [1][2] - The company's lead product, ExoPTEN, aims to address central nervous system injuries, which impose significant personal and economic burdens [2][5] - NurExone will present its exosome-based regenerative therapy platform at the Falling Walls Science Summit in Berlin from November 6-9, 2025 [2][5] Company Overview - NurExone is a biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries, with a strong emphasis on treating acute spinal cord and optic nerve injuries [5] - The company has received Orphan Drug Designation, facilitating its roadmap towards clinical trials in the U.S. and Europe [5] - NurExone has established Exo-Top Inc., a U.S. subsidiary, to support its North American growth strategy [5] Event Participation - As a finalist, NurExone will have access to exclusive networking events, connecting with investors, strategic partners, and global thought leaders [3] - The Falling Walls Venture serves as an international platform for science start-ups, with one winner being awarded the title 'Science Breakthrough of the Year' [4]

Core Viewpoint - NurExone Biologic Inc. announced preclinical results showing that 100% of small animals treated with a higher dose of ExoPTEN regained motor function after spinal cord injury, indicating significant therapeutic potential for the treatment of such injuries [4][5][6]. Group 1: Study Results - The study utilized the CatWalk XT system to assess the effects of ExoPTEN on animal locomotion, revealing that all animals in the high-dose group exhibited measurable gait recovery, while only one animal in the untreated group showed minimal improvement [5][6]. - A dose-dependent effect was observed, with 100% of animals in the high-dose group regaining walking ability in both hind limbs, compared to 50% in the medium-dose group and only 1 out of 6 in the untreated control group [6]. - Gait analysis demonstrated improvements in various parameters, including larger hind paw print areas, greater maximum contact area, wider base of support, and extended duration of paw contact with the walkway, reflecting enhanced balance and coordination [6][7]. Group 2: Future Plans and Development - The company plans to initiate additional studies to explore alternative dosing regimens and optimize ExoPTEN's manufacturing processes and analytical methods, aiming to refine the drug's therapeutic profile [7][9]. - NurExone is preparing for regulatory submissions and aims to launch first-in-human clinical trials, focusing on developing treatments for nervous system injuries [9][10]. - The company has established Exo-Top Inc., a U.S. subsidiary, to support its North American growth strategy and enhance its market presence [10].

Core Viewpoint - NurExone Biologic Inc. is advancing its exosome-based therapy platform, particularly focusing on its lead candidate ExoPTEN, which targets high-impact neurological conditions. The company is also seeking shareholder approval for its amended Omnibus Plan at an upcoming meeting [1][6]. Manufacturing Process and Clinical Readiness - The company presented promising early data on the viability and potency of cells from its proprietary Master Cell Bank (MCB) at a recent conference, indicating strong economic potential for exosome production [2][3]. - The MCB is crucial for establishing GMP-compliant manufacturing processes for exosomes, which are intended to support clinical trials and future commercial supply [3][4]. - NurExone plans to transfer its manufacturing process to its U.S.-based subsidiary, Exo-Top, to enhance clinical readiness and scalability [3][4]. Product Development and Market Potential - ExoPTEN is being developed as a first-in-class therapy for conditions such as acute spinal cord injury and optic nerve damage, which represent multi-billion-dollar markets [4][9]. - The company expects to initiate its first human clinical trial for ExoPTEN in 2026, continuing to expand its manufacturing capabilities for exosome-based regenerative therapies [5][9]. Omnibus Plan and Shareholder Approval - At the upcoming meeting, shareholders will consider the amended Omnibus Plan, which includes housekeeping amendments that do not affect securityholder rights [6][7]. - The maximum number of common shares reserved for RSUs and Restricted Shares is fixed at 10% of the issued and outstanding shares, currently anticipated to be 7,800,791 [8].

TORONTO and HAIFA, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that Professor Nahshon Knoller M.D., senior clinical advisor to the Company, will be presenting at the prestigious annual meeting of the American Spinal Injury Association (“ASIA”), where he will discuss the Company’s plans for future clinical trials in 2026 in the field of acute spinal cord injuries (“SCI”) for ExoPTEN, a first-in-clas ...

Core Insights - NurExone Biologic Inc. is a preclinical-stage biotechnology company focused on exosome-based therapies for central nervous system injuries, recently announcing its financial results for Q1 2025 and corporate updates [1][10] Financial Performance - The company reported a net loss of US$1.68 million for Q1 2025, an increase from a net loss of US$0.92 million in Q1 2024 [9] - Research and development expenses rose to US$0.62 million in Q1 2025 from US$0.23 million in Q1 2024, primarily due to non-cash stock-based compensation and increased subcontractor costs [8] - General and administrative expenses increased to US$1.08 million in Q1 2025 from US$0.70 million in Q1 2024, driven by higher legal and professional service costs [8] Capital Raising Activities - The company raised approximately C$480 thousand through a private placement of 856,996 units at $0.56 per unit on January 21, 2025 [5] - An additional C$866 thousand was raised through the exercise of Class A Warrants, with 2,140,456 warrants exercised at a price of $0.34 each [6] - On April 22, 2025, NurExone completed another private placement, raising approximately C$2.3 million, which will be used to advance clinical development activities [14] Business Developments - NurExone was included in the 2025 TSX Venture 50™ list, marking it as a top-performing company on the TSX Venture Exchange, with a 110% share price appreciation and a 209% increase in market cap [3] - The company established a U.S. subsidiary, Exo-Top Inc., to focus on the production and commercialization of exosomes, enhancing strategic flexibility and cost efficiency [4] Product Development - The lead product, ExoPTEN, has shown promising preclinical data for treating acute spinal cord and optic nerve injuries, with plans for first-in-human trials expected in 2026 [13][14] - Recent presentations at industry conferences highlighted significant advancements in optic nerve regeneration and facial nerve repair, validating the therapeutic potential of the ExoPTEN platform [14] Management Commentary - The CEO emphasized the company's progress in demonstrating functional recovery across various nerve injuries and the preparation for clinical trials [11] - The CFO noted that the financial results reflect disciplined investment in clinical programs and infrastructure, strengthening the cash position for advancing the ExoPTEN program [12]